High ROIC Stocks
VRTX is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
VERTEX PHARMACEUTICALS INC (VRTX) Stock Price & Overview
NASDAQ:VRTX • US92532F1003
Current stock price
438.71 USD
-8.55 (-1.91%)
At close:
438.71 USD
0 (0%)
After Hours:
The current stock price of VRTX is 438.71 USD. Today VRTX is down by -1.91%. In the past month the price decreased by -4.8%. In the past year, price decreased by -7.57%.
VRTX Key Statistics
52-Week Range362.5 - 510.77
Current VRTX stock price positioned within its 52-week range.
1-Month Range431.01 - 507.92
Current VRTX stock price positioned within its 1-month range.
- Market Cap
- 111.446B
- P/E
- 23.83
- Fwd P/E
- 22.63
- EPS (TTM)
- 18.41
- Dividend Yield
- N/A
VRTX Stock Performance
Today
-1.91%
1 Week
-3.31%
1 Month
-4.80%
3 Months
-2.97%
Longer-term
6 Months +8.78%
1 Year -7.57%
2 Years +11.68%
3 Years +28.76%
5 Years +101.06%
10 Years +420.17%
VRTX Stock Chart
VRTX Stock Screens
VRTX currently appears in the following ChartMill screener lists.
High Quality Stocks
VRTX is part of our High Quality Stocks screen, meaning it meets strict criteria for profitability, capital efficiency, and long-term growth consistency.
VRTX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VRTX. When comparing the yearly performance of all stocks, VRTX is a bad performer in the overall market: 75.24% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
VRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to VRTX. VRTX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
VRTX Earnings
On February 12, 2026 VRTX reported an EPS of 5.03 and a revenue of 3.19B. The company missed EPS expectations (-2.79% surprise) and missed revenue expectations (-1.51% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$5.03
Revenue Reported3.19B
EPS Surprise -2.79%
Revenue Surprise -1.51%
VRTX Forecast & Estimates
39 analysts have analysed VRTX and the average price target is 557.95 USD. This implies a price increase of 27.18% is expected in the next year compared to the current price of 438.71.
For the next year, analysts expect an EPS growth of 5.3% and a revenue growth 8.81% for VRTX
Analysts
Analysts81.03
Price Target557.95 (27.18%)
EPS Next Y5.3%
Revenue Next Year8.81%
VRTX Groups
Sector & Classification
Sector
Health Care Sub-Industry
Biotechnology VRTX Financial Highlights
Over the last trailing twelve months VRTX reported a non-GAAP Earnings per Share(EPS) of 18.41. The EPS increased by 6248.28% compared to the year before.
Income Statements
Revenue(TTM)12.00B
Net Income(TTM)3.95B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.94% | ||
| ROA | 15.42% | ||
| ROE | 21.18% | ||
| Debt/Equity | 0.01 |
Chartmill High Growth Momentum
EPS Q2Q%26.38%
Sales Q2Q%9.55%
EPS 1Y (TTM)6248.28%
Revenue 1Y (TTM)8.9%
VRTX Ownership
Ownership
Inst Owners97.75%
Shares254.03M
Float253.51M
Ins Owners0.15%
Short Float %1.63%
Short Ratio2.7
VRTX Latest News, Press Relases and Analysis
5 hours ago - By: Chartmill
6 days ago - By: Chartmill
VRTX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VRTX
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
IPO: 1991-07-24
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS 02210 US
CEO: Reshma Kewalramani
Employees: 6400
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / VRTX FAQ
Can you describe the business of VERTEX PHARMACEUTICALS INC?
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
What is the current price of VRTX stock?
The current stock price of VRTX is 438.71 USD. The price decreased by -1.91% in the last trading session.
Does VERTEX PHARMACEUTICALS INC pay dividends?
VRTX does not pay a dividend.
How is the ChartMill rating for VERTEX PHARMACEUTICALS INC?
VRTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the expected growth for VRTX stock?
The Revenue of VERTEX PHARMACEUTICALS INC (VRTX) is expected to grow by 8.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns VERTEX PHARMACEUTICALS INC?
You can find the ownership structure of VERTEX PHARMACEUTICALS INC (VRTX) on the Ownership tab.